AKT is a central effector of class I PI3K signaling, however, PIK3CA-mutant ER+ breast cancers show little AKT activation compared with alterations in other PI3K pathway components, and frequently exhibit AKT-independent tumor growth [97,98]. This evidence concerns the gene AKT1 and breast carcinoma.